參考文獻(xiàn)

[1]張婷,向波,林勇平.腫瘤標(biāo)志物聯(lián)合檢測(cè)在肺癌輔助診斷中的預(yù)測(cè)價(jià)值[J].中華預(yù)防醫(yī)學(xué)雜志,2021,55(6):786-791.DOI:10.3760/cma.j.cn112150-20200715-01015.

[2] Yang G, Xiao Z, Tang C, Deng Y, Huang H, He Z. Recent advances in biosensor for detection of lung cancer biomarkers. Biosens Bioelectron. 2019 Sep 15;141:111416. doi: 10.1016/j.bios.2019.111416. Epub 2019 Jun 6. PMID: 31279179.

[3]中華醫(yī)學(xué)會(huì)腫瘤學(xué)分會(huì),中華醫(yī)學(xué)會(huì)雜志社.中華醫(yī)學(xué)會(huì)腫瘤學(xué)分會(huì)肺癌臨床診療指南(2021版)[J].中華腫瘤雜志,2021,43(6):591-621.DOI:10.3760/cma.j.cn112152-20210207-00118.

Yang Q, Zhang P, Wu R, Lu K, Zhou H. Identifying the Best Marker Combination in CEA, [4]CA125, [4]CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible? Dis Markers. 2018 Oct 1;2018:2082840. doi: 10.1155/2018/2082840. PMID: 30364165; PMCID: PMC6188592.

[5]中華醫(yī)學(xué)會(huì)檢驗(yàn)分會(huì),衛(wèi)生部臨床檢驗(yàn)中心,中華檢驗(yàn)醫(yī)學(xué)雜志編輯委員會(huì).腫瘤標(biāo)志物的臨床應(yīng)用建議[J].中華檢驗(yàn)醫(yī)學(xué)雜志,2012,35(2):103-116.DOI:10.3760/cma.j.issn.1009-9158.2012.02.003.

[6]胡楠,劉琳,曾媛,焦宗林,金時(shí).血清癌胚抗原與肺癌關(guān)系的研究進(jìn)展[J].癌癥進(jìn)展,2020,18(6):547-548,602.DOI:10.11877/j.issn.1672-1535.2020.18.06.03.

[7]Ren H, Hu Y, Xie T, Jin C, Hu Y, Yang B. Effect of gefitinib on serum EGFR and CYFRA21-1 in patients with advanced non-small cell lung cancer. Oncol Lett. 2019 Oct;18(4):4167-4175. doi: 10.3892/ol.2019.10762. Epub 2019 Aug 16. PMID: 31516615; PMCID: PMC6732996.

[8]農(nóng)靖穎,顧艷斐,張毅.晚期非小細(xì)胞肺癌免疫治療預(yù)測(cè)生物標(biāo)志物的研究進(jìn)展[J].中華肺部疾病雜志（電子版）,2021,14(4):536-538.DOI:10.3877/cma.j.issn.1674-6902.2021.04.039.